ACU-4429, Visual Cycle Modulator, for Dry AMD: Acucela


Description: Acucela is conducting a Phase II clinical trial in the U.S. of ACU-4429, an orally administered visual cycle modulator, for the treatment of dry age-related macular degeneration (AMD). A total of 84 people may be enrolled in the study. By slowing the visual cycle, the drug is intended to reduce the build-up of toxic by-products in the retina (retinal pigment epithelium) that cause vision loss in dry AMD and potentially other retinal conditions. The drug has shown promising results in a preclinical study and a Phase I clinical trial.

Trial Status: Ongoing, recruiting.

Promising Dry AMD Treatment Moves into Phase II Clinical Trial

Partial List of Participation Criteria:

  1. Diagnosis of geographic atrophy (advanced dry AMD)

Clinical Trial Contacts:
Charles Yoon
(310) 289-2478 ext. 112
Retina-Vitreous Associates Medical Group
Beverly Hills, CA

Stephanie Pace, R.N.
(386) 366-6425
Covance Clinical Research Unit
Daytona Beach, FL

Cheryl Kiesel, C.C.R.C.
(239) 938-1284
National Ophthalmic Research Unit
Fort Meyers, FL

Amelita Sellona
(808) 441-6394
Covance Clinical Research Unit
Honolulu, HI

Jennifer Upton
(214) 647-9314
Covance Clinical Research Unit
Dallas, TX

Additional Information:
ACU-4429 clinical trial listing on